Financière de Tubize SAの内部者の所有権
Financière de Tubize SAの内部者の所有権は何ですか。
Financière de Tubize SAの内部者の所有権は56.85%です。
内部者の所有権の定義は何ですか。
管理の所有権(Insider Ownership)は、発行済株式総数で除したインサイダー（5％超を所有する株主または取締役または役員) が所有する株式総数によって計算されます。
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
EURONEXTのセクタHealth Careにおける内部者の所有権の企業と比べるFinancière de Tubize SA
Financière de Tubize SAは何をしますか。
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Financière de Tubize SAと類似の内部者の所有権
- Las Vegas Sandsの内部者の所有権は56.80%です。
- Kakatiya Cement Sugar and Industriesの内部者の所有権は56.81%です。
- McChip Resourcesの内部者の所有権は56.82%です。
- Laurus Labsの内部者の所有権は56.83%です。
- Reitmans (Canada)の内部者の所有権は56.84%です。
- Tecnoglass Incの内部者の所有権は56.85%です。
- Financière de Tubize SAの内部者の所有権は56.85%です。
- Fairfax Africaの内部者の所有権は56.86%です。
- Conart Engineersの内部者の所有権は56.86%です。
- Moelis Australiaの内部者の所有権は56.86%です。
- Western Pacific Trustの内部者の所有権は56.87%です。
- Crexendoの内部者の所有権は56.88%です。
- Helios Fairfax Partnersの内部者の所有権は56.88%です。